Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiovascular
Biotech
Keros halts 2 arms of hypertension trial over fluid near heart
Keros has halted dosing in two arms of a phase 2 trial of its pulmonary arterial hypertension drug over reports of fluid buildups around the heart.
James Waldron
Dec 12, 2024 6:30am
Windtree's shock med raises blood pressure in latest phase 2 win
Sep 25, 2024 9:59am
Medera plans SPAC merger to advance cardiac gene therapies
Sep 5, 2024 10:50am
Pfizer and Flagship add Quotient to multibillion-dollar equation
Aug 28, 2024 6:30am
Despite cash infusion, Windtree still needs rescue within a year
Aug 21, 2024 5:45am
Arrowhead dips toes into obesity pond with 2 preclinical assets
Aug 14, 2024 3:50pm
